Genmab — November 2017

[sowise]

nigen=noget

[sowise]

nogen

[StockBull]

Kursen kryber opad

[JohnW]

Ok. Jeg kan ikke bedømme ud fra linket.

[E_L]

on twitter i see this
JOHNSON & JOHNSON'S DARZALEX PLUS STANDARD DRUGS CUTS MULTIPLE MYELOMA PROGRESSION RISK 50 PCT VS STANDARD REGIMEN-STUDY #GEN

[E_L]

could be spam

[jkj]

ORR 90,9

[sowise]

?

[E_L]

reuters https://www.reuters.com/article/health-johnsonjohnson-myeloma/jj-multiple-myeloma-drug-succeeds-in-first-line-combination-study-idUSL1N1NQ1TK

[JKY_VH]

Tak E L , bibob og jkj

[GeorgeBest]

Thanks E L

[jkj]

ikke late breaker såvidt jeg kan se ,
præsenteres på næste ash møde om 1 måned ifølge reuters

[jkj]

eller hva ?

[gentogen]

Tak for link. Ser solidt ud.

[gentogen]

The rate of complete responses, meaning no detectable cancer in the blood or bone marrow, was 42.6 percent for Darzalex versus 24.4 percent for the standard regimen.

[rex_pacis]

thanks @e

[sowise]

en kurs
belønning kom der ikke ud af det

[Bulder]

Det er lavere CR end Pollux i 2. linje

[OHW]

Data er ikke interessante nok til at løfte kursen..

[JKY_VH]

"Dr. Kenneth Anderson, the ASH president, called the responses “impressive,” but added they were likely to be viewed as even more significant outside the United States.
The trial was primarily conducted in Europe using the standard first-line regimen there. Celgene Corp’s Revlimid is part of the standard regimen used in the United States.
“It likely will be the basis for approval of daratumumab to be incorporated into the initial combination therapy of myeloma,” Anderson said of the results."